274 related articles for article (PubMed ID: 26914924)
41. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
42. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
43. Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation.
Gruchot J; Lein F; Lewen I; Reiche L; Weyers V; Petzsch P; Göttle P; Köhrer K; Hartung HP; Küry P; Kremer D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362063
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
45. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.
Sabsabi S; Mikhael E; Jalkh G; Macaron G; Rensel M
Patient Prefer Adherence; 2022; 16():1307-1319. PubMed ID: 35637684
[TBL] [Abstract][Full Text] [Related]
46. Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
Sartawi Z; Ryan KB; Waeber C
Eur J Pharmacol; 2020 Sep; 882():173262. PubMed ID: 32534075
[TBL] [Abstract][Full Text] [Related]
47. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Yagi Y; Nakamura Y; Kitahara K; Harada T; Kato K; Ninomiya T; Cao X; Ohara H; Izumi-Nakaseko H; Suzuki K; Ando K; Sugiyama A
Toxicol Appl Pharmacol; 2014 Nov; 281(1):39-47. PubMed ID: 25223691
[TBL] [Abstract][Full Text] [Related]
48. Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
Leavitt VM; Rocca M
Neurology; 2021 Jan; 96(3):91-92. PubMed ID: 33328322
[No Abstract] [Full Text] [Related]
49. Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.
Snelder N; Ploeger BA; Luttringer O; Rigel DF; Webb RL; Feldman D; Fu F; Beil M; Jin L; Stanski DR; Danhof M
J Pharmacol Exp Ther; 2017 Feb; 360(2):356-367. PubMed ID: 27934627
[TBL] [Abstract][Full Text] [Related]
50. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
51. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
52. Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review.
Li Q; Jing LJ; Li Y; Jia Y
BMC Neurol; 2023 Jul; 23(1):286. PubMed ID: 37525104
[TBL] [Abstract][Full Text] [Related]
53. Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article.
Cohan S; Lucassen E; Smoot K; Brink J; Chen C
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32708516
[TBL] [Abstract][Full Text] [Related]
54. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
[TBL] [Abstract][Full Text] [Related]
55. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
[No Abstract] [Full Text] [Related]
56. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
[TBL] [Abstract][Full Text] [Related]
57. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Gardin A; Gray C; Neelakantham S; Huth F; Davidson AM; Dumitras S; Legangneux E; Shakeri-Nejad K
Eur J Clin Pharmacol; 2018 Dec; 74(12):1593-1604. PubMed ID: 30105453
[TBL] [Abstract][Full Text] [Related]
58. Migraine, interferon β1a and siponimod immunomodulator therapies.
Dahaba AA; Bornemann-Cimenti H
BMC Anesthesiol; 2022 Apr; 22(1):95. PubMed ID: 35382764
[TBL] [Abstract][Full Text] [Related]
59. Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
Bigaud M; Ramseier P; Tisserand S; Lang M; Urban B; Beerli C; Karlsson G
Neurol Ther; 2023 Aug; 12(4):1187-1203. PubMed ID: 37195409
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
